Thursday, March 21, 2013 4:40:52 PM
I take it most do not know who "BioBreakthrough" is and his trackrecord
In answer to the queries being posted, YES, it was his tweet that caused the high volume explosion in the PPS of IGC shares.
Look at the time of his tweet then see the volume occur at the same identical time.
Those that subscribe to realtime chat services, were able to identify this in a very expedient manner then decide to buy/sell/hold based upon their credence in this individual's past track record.
Feel free to conduct further due diligence on the individual. You may walk away with a firmer understanding of why the shares spiked on one man's mention.
He will be composing an article on IGC. It is not out yet.
I tend to sell AHEAD of such things.
But thats just me.
Bricoleur was thrown for a loop today, as RETAIL dominated the volume.
But I never did subscribe to the Bricoleur theory.
Regardless, i sold half my position.
In answer to the queries being posted, YES, it was his tweet that caused the high volume explosion in the PPS of IGC shares.
Look at the time of his tweet then see the volume occur at the same identical time.
Those that subscribe to realtime chat services, were able to identify this in a very expedient manner then decide to buy/sell/hold based upon their credence in this individual's past track record.
Feel free to conduct further due diligence on the individual. You may walk away with a firmer understanding of why the shares spiked on one man's mention.
He will be composing an article on IGC. It is not out yet.
I tend to sell AHEAD of such things.
But thats just me.
Bricoleur was thrown for a loop today, as RETAIL dominated the volume.
But I never did subscribe to the Bricoleur theory.
Regardless, i sold half my position.
Recent IGC News
- IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment • ACCESS Newswire • 05/19/2026 09:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 08:02:08 PM
- IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference • ACCESS Newswire • 05/15/2026 12:00:00 PM
- IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase • ACCESS Newswire • 04/28/2026 04:15:00 PM
- IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion • ACCESS Newswire • 04/22/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/20/2026 08:01:33 PM
- IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia • ACCESS Newswire • 04/20/2026 12:30:00 PM
- IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout • ACCESS Newswire • 04/14/2026 12:30:00 PM
- Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts • ACCESS Newswire • 04/08/2026 04:45:00 PM
- IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease • ACCESS Newswire • 04/07/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 08:02:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 08:01:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 09:43:01 PM
- IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness • ACCESS Newswire • 03/30/2026 12:00:00 PM
- IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025 • ACCESS Newswire • 03/19/2026 01:00:00 PM
- IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026 • ACCESS Newswire • 03/18/2026 01:00:00 PM
- IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research • ACCESS Newswire • 02/26/2026 01:30:00 PM
- IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets • ACCESS Newswire • 02/24/2026 01:30:00 PM
- IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial • ACCESS Newswire • 02/23/2026 01:30:00 PM
- IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances • ACCESS Newswire • 02/17/2026 01:30:00 PM
- IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets • ACCESS Newswire • 02/12/2026 01:30:00 PM
- IGC Pharma Announces Equity Research Update by Alliance Global Partners • ACCESS Newswire • 02/10/2026 01:30:00 PM
- IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center • ACCESS Newswire • 02/09/2026 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 09:02:27 PM
